Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETECT I
NCT05289661Phase 3Active, not recruiting
- Sponsor
- Stanford University
- Start
- Jul 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ripasudil in Fuchs endothelial corneal dystrophy (FECD), pseudophakic corneal edema (PCE), Iridocorneal Endothelial Syndrome (ICE), Posterior Polymorphous Corneal Dystrophy (PPCD), sponsored by Stanford University. Started Jul 2022; status: active, not recruiting.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial corneal dystrophy (FECD)pseudophakic corneal edema (PCE)Iridocorneal Endothelial Syndrome (ICE)Posterior Polymorphous Corneal Dystrophy (PPCD)
Beyond the preview
Go deeper on NCT05289661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289661.